CCG-100602 – 5 mg

Brand:
Cayman
CAS:
1207113-88-9
Storage:
-20
UN-No:
Non-Hazardous - /

The Rho family of small GTPases play an important role in transduction of cell signaling events associated with several human cancers. CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. The site of inhibition in the pathway is not precisely defined but CCG-1423 appears to act on some aspect of the interaction of SRF with its transcriptional cofactor megakaryoblastic leukemia 1 (MKL1) at a point upstream of DNA binding.{15012} CCG-100602 is a CCG-1423 analog developed for improved selectivity, potency, and attenuated cytotoxicity relative to its parent compound. CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells with an IC50 value of 9.8 µM. At 100 μM, CCG-100602 demonstrates 72% inhibition of PC-3 cell invasion into a Matrigel model of metastasis, exhibiting an efficacy:toxicity profile superior to that of CCG-1423 at 10 μM.{19162}  

 

Available on backorder

SKU: 10787 - 5 mg Category:

Description

Inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC3 prostate cancer cells with an IC50 value of 9.8 µM


Formal name: 1-[3,5-bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-3-piperidinecarboxamide

Synonyms: 

Molecular weight: 478.8

CAS: 1207113-88-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Cancer|Cell Signaling